Misplaced Pages

Tariquidar

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound
This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this article by introducing citations to additional sources.
Find sources: "Tariquidar" – news · newspapers · books · scholar · JSTOR (August 2014)
Pharmaceutical compound
Tariquidar
Clinical data
ATC code
  • none
Identifiers
IUPAC name
  • N-phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC38H38N4O6
Molar mass646.744 g·mol
3D model (JSmol)
SMILES
  • COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)NC(=O)C4=CC(=C(C=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC)OC)OC
InChI
  • InChI=1S/C38H38N4O6/c1-45-33-18-25-14-16-42(23-28(25)19-34(33)46-2)15-13-24-9-11-29(12-10-24)40-38(44)30-20-35(47-3)36(48-4)21-32(30)41-37(43)27-17-26-7-5-6-8-31(26)39-22-27/h5-12,17-22H,13-16,23H2,1-4H3,(H,40,44)(H,41,43)
  • Key:LGGHDPFKSSRQNS-UHFFFAOYSA-N
  (what is this?)  (verify)

Tariquidar (INN/USAN) is a P-glycoprotein inhibitor undergoing research as an adjuvant against multidrug resistance in cancer.

References

  1. Robey RW, Shukla S, Finley EM, Oldham RK, Barnett D, Ambudkar SV, Fojo T, Bates SE (March 2008). "Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R))". Biochemical Pharmacology. 75 (6): 1302–12. doi:10.1016/j.bcp.2007.12.001. PMC 2346578. PMID 18234154.
Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: